Colonic Navigational Nanotechnology helps Deliver Drugs to Intestinal Target

Several drugs would have therapeutic effects that are more beneficial if they could be targeted at absorption by the lower intestine. However, in order to target the colon for treating colon cancer for instance, medication delivered by mouth must surmount several barriers including stomach acidity, binding to mucus layers, rapid clearance from the gut, and premature uptake by cells higher up the gastrointestinal tract. Being able to deliver a drug by mouth has several advantages over injection or suppository: ease of dosing, for instance, and better patient compliance.

Various techniques have been employed, including coating drug molecules with a polymer shell. However, Drs. Kevin P. O'Donnell and Robert O. Williams III, of the division of pharmaceutics, at the University of Texas at Austin (USA), have reviewed the various techniques available and suggested that encapsulating a drug molecule within nanoparticles offers the best option for controlling drug delivery and targeting the colon.

The investigators have reviewed the state-of-the-art in nanotechnology for delivery of therapeutic agents to the colon. They explained that developments in particle engineering techniques have recently made it possible to made drug products on the nanoscale. Techniques such as spray drying, antisolvent methods, dialysis methods, emulsion and cryogenic methods are all now available for drug formulation. Transforming a drug powder into nanoparticles can often render a compound that is poorly soluble in water, soluble, or increase bioavailability simply through an increase in the surface area to volume ratio. Smaller particles mean a bigger surface area to interact with absorbing surfaces in the gastrointestinal tract. Moreover, fatty but solid nanoparticles of the compound quercetin (a health supplement) are absorbed almost six times more effectively by the gut in nanoparticle form than the common drug suspension formulation.

The researchers reported that that nanoparticle drug delivery could be particularly advantageous for patients suffering from inflammatory bowel diseases including Crohn's Disease, ulcerative colitis, and irritable bowel syndrome, all which often require long-term treatment. However, they also noted that because there are no digestive enzymes in the colon and its neutral pH, it is a prime target for the delivery of therapeutic proteins, peptides, viral vectors, and nucleotides for a wide range of disease, not only for those associated with the colon.

The study's findings were published November 2010 in the International Journal of Nanotechnology.

Related Links:
University of Texas